Swanbridge Capital
  • Home
  • Our Story
  • Strategy
  • Portfolio
  • Team
  • News & Events
  • Contact
Select Page

Allero Therapeutics secures seed investment from Swanbridge Capital

by stefan | Apr 17, 2019 | Blog

ROTTERDAM, 17 April 2019 – Swanbridge Capital, an early-stage Life Sciences venture capital fund, today announced the closing of a Seed investment in Allero Therapeutics, a biopharmaceutical company focused on the discovery and development of novel immunotherapies....

Recent Posts

  • Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program
  • Swanbridge Capital invests in Immagene
  • Curie Capital invests in Allero Therapeutics
  • Allero Therapeutics secures seed investment from Swanbridge Capital
  • DegenRx secures funding for Alzheimer’s disease gene therapy

Recent Comments

    Archives

    • November 2020
    • September 2020
    • October 2019
    • April 2019
    • December 2018
    • July 2018
    • December 2017
    • October 2017
    • December 2016

    Categories

    • Blog
    • Geen categorie

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • RSS

    Designed by Elegant Themes | Powered by WordPress